SHORT COMMUNICATION
Recommendations for diagnostic and therapeutic procedures in systemic onset juvenile idiopathic arthritis. The opinion of the Panel of Experts of the National Consultant in the field of rheumatology
Submission date: 2013-02-28
Final revision date: 2013-08-20
Acceptance date: 2013-09-11
Online publication date: 2013-10-31
Publication date: 2013-10-30
Reumatologia 2013;51(5):328-331
KEYWORDS
TOPICS
ABSTRACT
Systemic onset juvenile idiopathic arthritis (sJIA) occurs in 10% of patients with juvenile idiopathic arthritis and is manifested by hectic fever, typical rash, systemic symptoms, arthritis and high levels of inflammatory laboratory markers. In some cases of sJIA, response to treatment with standard therapy, including use of biologic medications blocking tumor necrosis factor (TNF), is poor. The efficacy of treatment depends on the rapid implementation of an appropriate therapeutic option. Treatment with interleukin 1 (IL-1) and interleukin 6 (IL-6) blockers is an effective alternative therapy in cases refractory to the most often used therapy.
REFERENCES (20)
1.
Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. W: Textbook of Pediatric Rheumatology. Cassidy J, Petty R (red.). Elsevier Inc. 2011; 236-248.
2.
Romicka A, Rostropowicz-Denisiewicz K. Choroby reumatyczne w wieku rozwojowym. W: Reumatologia kliniczna. Zimmermann--Górska I (red.). Wydawnictwo Lekarskie PZWL, Warszawa 2008.
3.
Cimaz R, Von Scheven A, Hofer M. Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease. Swiss Med Wkly 2012; 142: w13582.
4.
Cimaz R, Moretti D, Pagnini I, et al. What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis? Curr Rheumatol Rep 2012; 14: 150-154.
5.
Ling XB, Park JL, Carroll T. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 2010; 10: 4415-4430.
6.
Hinze CH, Fall N, Thornton S, et al. Immature cell populations and an erythropoesis gen expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther 2010; 12: R123.
7.
Tuszkiewicz-Misztal E, Olesińska E. Postępy w reumatologii wieku rozwojowego w 2009 roku. Medycyna Praktyczna 2010; 5: 28-33.
8.
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392.
9.
Romicka A. Młodzieńcze idiopatyczne zapalenie stawów – obraz kliniczny, przebieg i leczenie. Standardy medyczne. Pediatria 2010; 7: 189-193.
10.
Rutkowska-Sak L, Gietka P, Wierzbowska M. Zalecenia postępowania diagnostycznego i terapeutycznego. Reumatologia wieku rozwojowego. Reumatologia 2012; 50: 142-161.
11.
Tsai HY, Lee JH, Yu HH. Initial manifestations and clinical course of systemic onset juvenile idiopathic arthritis: a ten-year retrospective study. J Formos Med Assoc 2012; 111: 542-549.
12.
De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients (pts) with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data. Presented at EULAR 2011. Ann Rheum Dis 2011; 70 (Suppl 3): 67.
13.
Batthish M, Feldman BM, Babyn PS, et al. Predictors of hip disease in the systemic arthritis subtype of juvenile idiopathic arthritis. J Rheumatol 2011; 38: 954-958.
14.
Ravelli A, Lattanzi B, Consolaro A, Martini A. Glucocorticoids in pediatric rheumatology. Clin Exp Rheumatol 2011; 29 (5 Suppl 68): S148-S152.
15.
Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 2010; 77: 511-516.
16.
DeWitt EM, Kimura Y, Beukelman T, et al.; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1001-1010.
17.
Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-482.
18.
Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
19.
Kaly L, Rosner I. Tocilizumab – a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26: 157-165.
20.
Zuber Z, Rutkowska-Sak L, Postępski J. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit 2011; 17: SR35-42.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
